The company has maintained zero commercial revenue over the last ten quarters while sustaining quarterly operating losses that frequently exceed $2 million.
| Metric | TTM | Jun'25 | Jun'24 | Jun'23 | Jun'22 | Jun'21 | Jun'20 | Jun'19 | Jun'18 | Jun'17 | Jun'16 | Jun'15 | Jun'14 | Jun'13 | Jun'12 | Jun'11 | Jun'10 | Jun'09 | Jun'08 | Jun'07 | Jun'06 | Jun'05 |
|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 129.63K | 0 | 0 | 0 | 0 | 0 | 0 | 695.91K | 680.06K | 662.95K | 659.54K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -129.63K | 0 | 0 | 0 | 0 | 0 | 0 | -695.91K | -680.06K | -662.95K | -659.54K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | 100% | -2.33% | -2.58% | -0.52% | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 8.05M | 9.59M | 8.52M | 8.94M | 8.11M | 8.74M | 8M | 8.66M | 9.33M | 9.6M | 8.86M | 7.06M | 8.67M | 6.59M | 6.08M | 6.43M | 4.94M | 2.82M | 2.79M | 3.08M | 2.6M | 66K |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 744.28B | 4.04M | 3.08M | 2.55M | 2.33M | 2.63M | 3.3M | 2.74M | 4.5M | 4.07M | 3.83M | 3.4M | 3.54M | 2.3M | 1.82M | 2.27M | 1.74M | 1.09M | 1.95M | 2.35M | 1.7M | 35.23K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 1.29T | 5.55M | 5.44M | 6.39M | 5.78M | 6.11M | 4.7M | 5.92M | 4.83M | 5.53M | 5.03M | 3.66M | 5.13M | 4.29M | 4.27M | 4.16M | 3.2M | 1.73M | 839.24K | 731.81K | 899.89K | 30.77K |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -1000K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -8.18M | -9.59M | -8.52M | -8.94M | -8.11M | -8.74M | -8M | -8.66M | -9.33M | -9.6M | -8.86M | -7.06M | -8.67M | -6.59M | -6.08M | -6.43M | -4.94M | -2.82M | -2.79M | -3.08M | -2.6M | -66K |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -12.63% | 4.78% | -10.23% | 7.21% | -9.35% | 7.66% | 7.14% | 2.87% | -8.37% | -25.43% | 18.51% | -31.52% | -8.36% | 5.41% | -30.15% | -75.19% | -0.99% | 9.43% | -18.76% | -3832.81% | - |
| EBITDA | -7.62M | -8.85M | -7.76M | -8.2M | -7.39M | -8.04M | -7.3M | -7.96M | -8.65M | -8.94M | -8.2M | -6.76M | -8.46M | -6.37M | -5.86M | -5.9M | -4.85M | -2.81M | -2.78M | -3.05M | -2.55M | -66K |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 16.22% | -14.06% | 5.35% | -10.9% | 8.08% | -10.18% | 8.38% | 7.88% | 3.27% | -9% | -21.29% | 20.05% | -32.72% | -8.68% | 0.67% | -21.69% | -72.74% | -1.04% | 8.8% | -19.41% | -3765.3% | - |
| D&A (Non-Cash Add-back) | 556.66K | 743.8K | 759.01K | 747.53K | 723.33K | 704.54K | 699.72K | 695.91K | 680.06K | 662.95K | 659.54K | 302.74K | 212.01K | 219.65K | 219.65K | 527.74K | 90.29K | 12.29K | 13.47K | 36.3K | 44.55K | 0 |
| EBIT | -8.13M | -9.47M | -8.24M | -8.59M | -8.1M | -8.74M | -8M | -8.66M | -9.27M | -9.6M | -8.86M | -7.06M | -8.67M | -7.78M | -6.21M | -6.48M | -4.74M | -2.85M | -2.74M | -3.03M | -2.59M | 0 |
| Net Interest Income | 84.69K | 124.83K | 221.97K | 354.89K | 6.74K | -76.06K | -76.59K | 55.5K | -444.06K | -2.07M | -2.41M | -3.66M | -3.49M | -1.04M | 0 | 0 | 0 | 0 | 0 | 137.43K | 0 | 0 |
| Interest Income | 84.69K | 124.83K | 271.77K | 355.83K | 11.86K | 9.35K | 17.08K | 55.5K | 100.43K | 60.95K | 62.64K | 160.86K | 171K | 55.59K | 46.79K | 14.34K | 0 | 31.93K | 0 | 54.51K | 0 | 0 |
| Interest Expense | 0 | 0 | 49.81K | 938 | 5.12K | 85.41K | 93.67K | 0 | 544.49K | 2.13M | 2.47M | 3.82M | 3.66M | 1.09M | 0 | 0 | 0 | 0 | 0 | 90.56K | 0 | 0 |
| Other Income/Expense | 84.69K | 124.68K | 221.97K | 354.89K | 6.74K | -78.08K | -5.45M | 235.24K | 761.71K | -703.77K | -1.87M | 4.86M | -4.93M | -2.29M | -125.46K | -47.71K | 358.27K | -26.2K | 53.7K | -36.05K | -688.58K | 0 |
| Pretax Income | -8.09M | -9.47M | -8.29M | -8.59M | -8.11M | -8.82M | -13.45M | -8.42M | -8.56M | -10.3M | -10.72M | -2.2M | -14.11M | -8.88M | -6.21M | -6.48M | -4.74M | -2.79T | 0 | 0 | 0 | 0 |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -179.75K | 0 | 0 | 0 | 0 | 3.66M | 0 | 0 | 47.71K | -195.74K | 31.93B | -53.7K | 36.05K | 688.58K | 66K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 2.13% | 0% | 0% | 0% | 0% | -25.96% | 0% | 0% | -0.74% | 4.13% | -1.15% | - | - | - | - |
| Net Income | -8.09M | -9.47M | -8.29M | -8.59M | -8.11M | -8.82M | -13.45M | -8.24M | -8.56M | -10.3M | -10.72M | -2.2M | -14.11M | -8.88M | -6.21M | -6.48M | -4.74M | -2.79M | -2.74M | -3.12M | -3.28M | -66K |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 16.82% | -14.14% | 3.43% | -5.94% | 8.11% | 34.39% | -63.09% | 3.72% | 16.9% | 3.92% | -387.89% | 84.42% | -58.93% | -42.99% | 4.17% | -36.53% | -70.18% | -1.81% | 12.2% | 5.04% | -4876.04% | - |
| Net Income (Continuing) | -8.09M | -9.47M | -8.29M | -8.59M | -8.11M | -8.82M | -13.45M | -8.42M | -8.56M | -10.3M | -10.72M | -2.2M | -13.6M | -8.88M | -6.21M | -6.48M | -4.74M | -2.79M | -2.74M | -3.12M | -3.28M | -66K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.37 | -0.63 | -0.70 | -0.74 | -0.70 | -0.81 | -2.39 | -2.30 | -2.64 | -3.43 | -3.72 | -0.74 | -5.51 | -3.73 | -2.90 | -3.26 | -2.54 | -1.63 | -1.64 | -1.94 | -2.22 | -0.05 |
| EPS Growth % | 39.14% | 10% | 5.41% | -5.71% | 13.58% | 66.11% | -3.91% | 12.88% | 23.03% | 7.8% | -402.7% | 86.57% | -47.72% | -28.62% | 11.04% | -28.35% | -55.83% | 0.61% | 15.46% | 12.61% | -4705.19% | - |
| EPS (Basic) | - | -0.63 | -0.70 | -0.74 | -0.70 | -0.81 | -2.39 | -2.30 | -2.64 | -3.43 | -3.72 | -0.78 | -5.51 | -3.87 | -2.90 | -3.26 | -2.54 | -1.63 | -1.64 | -1.94 | -2.22 | -0.05 |
| Diluted Shares Outstanding | 21.61M | 15.12M | 11.87M | 11.63M | 11.53M | 10.9M | 5.62M | 3.59M | 3.25M | 3.01M | 2.88M | 2.96M | 2.56M | 2.38M | 2.14M | 1.99M | 1.86M | 1.71M | 1.67M | 1.6M | 1.48M | 1.43M |
| Basic Shares Outstanding | 21.61M | 15.12M | 11.87M | 11.63M | 11.53M | 10.9M | 5.62M | 3.59M | 3.25M | 3.01M | 2.88M | 2.83M | 2.56M | 2.29M | 2.14M | 1.99M | 1.86M | 1.71M | 1.67M | 1.6M | 1.48M | 1.43M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Imminent liquidity and dilution risk
As evidenced by the company's historical financial statements, NanoViricides has maintained zero revenue across the last ten quarters, confirming its status as a pure-play clinical research entity that remains entirely dependent on external capital to fund its ongoing development of the proprietary nanoviricide platform technology.
The lack of top-line growth is consistent with the company's current stage of development, where value is derived from clinical milestones rather than product sales. Investors should monitor whether the company can transition from this pre-revenue state to a commercial model, as the current trajectory offers no evidence of market-validated demand.
According to recent SEC filings, the company's operating expenses consistently hover between $1.8 million and $3.2 million per quarter, reflecting a high fixed-cost structure driven by internal R&D and the maintenance of a specialized cGMP-compliant manufacturing facility in Shelton, Connecticut, despite the absence of product revenue.
The decision to internalize manufacturing capabilities appears to impose a significant, non-variable cost burden that exacerbates the company's cash burn. This strategy suggests management prioritizes operational control, yet it leaves the firm highly exposed to liquidity constraints during periods of prolonged clinical trial timelines.
Based on reported figures, the company's operating losses remain stubbornly high, with quarterly net losses frequently exceeding $2 million, indicating that the firm lacks the operating leverage necessary to scale its research activities efficiently without incurring substantial, recurring dilution for its existing shareholder base.
The absence of gross profit means that every dollar spent on R&D and SG&A flows directly to the bottom line as a loss. This structure implies that the company's financial health is entirely decoupled from operational efficiency, relying instead on the successful execution of clinical trials to justify its valuation.
As highlighted in the most recent financial data, the company's cash reserves of approximately $1.56 million appear insufficient to support its current quarterly burn rate, suggesting that the firm faces a critical inflection point that may necessitate immediate and potentially dilutive financing to maintain operations.
Short-sellers would likely focus on the widening gap between the company's cash runway and its ongoing R&D requirements. The reliance on equity markets to fund operations warrants further investigation, as the current financial position may limit the company's ability to advance its pipeline without significant shareholder dilution.
Quick answers to the most common questions about buying NNVC stock.
For fiscal year 2025, NanoViricides, Inc. (NNVC) reported total revenue of $0.0M.
NanoViricides, Inc. (NNVC) reported a net loss of $9.5M for the fiscal year ending 2025.